Propanc Biopharma, Inc. (PPCB)
NASDAQ: PPCB · Real-Time Price · USD
0.1916
-0.0111 (-5.48%)
At close: Feb 20, 2026, 4:00 PM EST
0.1901
-0.0015 (-0.78%)
After-hours: Feb 20, 2026, 7:50 PM EST

Propanc Biopharma Income Statement

Millions USD. Fiscal year is Jul - Jun.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Jun '25 Jun '24 Jun '23 Jun '22 Jun '21
Selling, General & Admin
64.9157.051.291.531.731.58
Research & Development
0.190.220.250.250.260.23
Operating Expenses
65.157.281.541.781.991.81
Operating Income
-65.1-57.28-1.54-1.78-1.99-1.81
Interest Expense
-0.72-0.56-0.67-0.53-0.57-0.45
Interest & Investment Income
00000.010
Currency Exchange Gain (Loss)
-0.07-0.090.020.01-0.040.03
Other Non Operating Income (Expenses)
0.46-0.120.18-0.53-0.1-0.01
EBT Excluding Unusual Items
-65.44-58.05-2-2.83-2.7-2.24
Other Unusual Items
-0.63-0.870.050.04-0.020.1
Pretax Income
-66.07-58.92-1.95-2.79-2.71-2.14
Income Tax Expense
---0.13-0.13-0.05-0.11
Net Income
-66.07-58.92-1.82-2.66-2.66-2.03
Preferred Dividends & Other Adjustments
0.93-0.190.470.70.39
Net Income to Common
-67-58.92-2.01-3.13-3.36-2.42
Shares Outstanding (Basic)
104----
Shares Outstanding (Diluted)
104----
EPS (Basic)
-6.45-14.85----
EPS (Diluted)
-6.45-14.85----
Free Cash Flow
-3.13-0.41-0.94-1.11-1.44-1.15
Free Cash Flow Per Share
-0.30-0.10----
EBITDA
-65.1-57.28-1.54-1.77-1.99-1.81
D&A For EBITDA
000000
EBIT
-65.1-57.28-1.54-1.78-1.99-1.81
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.